Incretin Atlas › Trials › UBT251 phase 2 obesity China (NCT07177469)
UBT251 phase 2 obesity China (NCT07177469)
UBT251 · obesity
Design
- Molecule(s)
- UBT251
- Population
- obesity
- Phase
- 2
- Participants
- 205
- Duration
- 24 weeks
- Registry
- NCT07177469
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.0 mg (initial dose 0.5 mg) | obesity china | 24 | 205 | — | —−16.2 % vs −2.0 % estimand not specified | — | — | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- 4.0 mg (initial dose 0.5 mg): Peer-reviewed paper (Cell Metab 2026) confirms the range of −13.6 % to −19.7 % vs −2.0 % with placebo at 24 weeks; per-dose values come from the EASD 2026 abstract until the full text is available.
Verbatim quotes from the source (1)
- 4.0 mg (initial dose 0.5 mg) · weight_unsp · abstract
change (95% CI) in weight being -13.6% (-15.3 to -11.8) in the 2.0 mg group, -16.2% (-18.7 to -13.6) in the 4.0 mg (ID, 0.5 mg)
Primary sources
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd63850.
- Zhou Z, Cheng Z, Jin P, Yang G, Wang H, Shi B, et al. UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial. Cell Metab. 2026. PMID: 42843337.
How to cite this page
Medical Adviser's Group. Incretin Atlas: UBT251 phase 2 obesity China (NCT07177469). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-obesity-china/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.